CTRI/2009/091/000959已完成2 期
A prospective, multicenter,investigator-blinded, randomized, comparative study to estimate safety,tolerability & efficasy of NXL104/Ceftazidime vs. Imipenem cilastatin followed by appropriate oral therapy in the treatment of complicated urinary tract infections in hospitalized adults
ovexel, Inc2250 Hickory Road, Suite 216Plymouth Meeting, PA 194620 个研究点目标入组 150 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Acute pyelonephritis or other complicated urinary tract infection due to gram negative pathogens
- •2. Ages Eligible for Study: 18 Years to 65 Years
- •3. Genders Eligible for Study: Both
排除标准
- •1. Ileal loops or vesicoureteral reflux
- •2. Complete obstruction of any portion of urinary tract, perinephric or intrarenal abscess.
- •3. Fungal urinary tract infection
- •4. Permanent indirect catheter or nephrostomy unless removed within 48 hours of study entry
- •5. History hypersensitivity to study medication
研究者
相似试验
进行中（未招募）
1 期
A multicenter study to evaluate pharmacokinetics, safety and tolerability of TIN816 in patients with sepsis-associated acute kidney injuryEUCTR2022-000887-23-DEovartis Pharma AG20
招募中
1 期
A multicenter study to evaluate pharmacokinetics, safety and tolerability of TIN816 in patients with sepsis-associated acute kidney injuryEUCTR2022-000887-23-ESovartis Farmacéutica, S.A.20
进行中（未招募）
1 期
A multicenter study to evaluate pharmacokinetics, safety and tolerability of TIN816 in patients with sepsis-associated acute kidney injuryEUCTR2022-000887-23-HUovartis Pharma AG20
进行中（未招募）
1 期
A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects with Chronic Inflammatory Demyelinating PolyradiculoneuropathyChronic inflammatory demyelinating polyradiculoneuropathy (CIDP)MedDRA version: 21.1Level: PTClassification code 10057645Term: Chronic inflammatory demyelinating polyradiculoneuropathySystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002411-17-BECB Biopharma SR34
进行中（未招募）
1 期
A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects with Chronic Inflammatory Demyelinating PolyradiculoneuropathyChronic inflammatory demyelinating polyradiculoneuropathy (CIDP)MedDRA version: 21.1Level: PTClassification code 10057645Term: Chronic inflammatory demyelinating polyradiculoneuropathySystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002411-17-DECB Biopharma SPR34